文章摘要

血栓通胶囊对视网膜中央静脉阻塞患者视网膜微循环、黄斑水肿及内皮素-1表达的影响

作者: 1徐思琪, 1龚雨婷, 1王林农, 1许译丹
1 南京医科大学附属南京医院眼科，南京 210006
通讯: 王林农 Email: linnongwang@aliyun.com
DOI: 10.3978/j.issn.2095-6959.2022.08.027

摘要

目的：研究血栓通胶囊对视网膜中央静脉阻塞患者视网膜微循环、黄斑水肿及内皮素-1(endothelin-1，ET-1)表达的影响。方法：收集2018年1月至2021年6月南京医科大学附属南京医院收治的116例视网膜中央静脉阻塞患者，根据患者的治疗方法分为实验组(n=58)与对照组(n=58)，对照组患者给予常规治疗，实验组在此基础上给予血栓通胶囊治疗。对比两组患者治疗前后视网膜中央动脉血流情况、黄斑中心凹厚度、ET-1水平、视网膜振荡电位(oscillatory potentials，OPs)波幅及潜伏期；对比两组患者治疗期间出现的不良反应。结果：治疗后，两组患者中央动脉收缩期峰值血流速度(peak systolic velocity，PSV)和舒张期血流速度(end diastolic velocity，EDV)均升高，且相比于对照组，实验组升高更显著(P<0.001)；治疗后，两组患者黄斑中心凹厚度水平均降低，且相比于对照组，实验组降低更显著(P<0.001)；治疗后，两组患者血清ET-1水平均降低，且相比于对照组，实验组降低更显著(P<0.001)；治疗后，两组患者OPs波幅前4子波(OP1、OP2、OP3和OP4)水平均显著升高，且实验组显著高于对照组(均P<0.001)；治疗后，两组患者OPs潜伏期OP1、OP2和OP3水平均显著降低，且实验组显著低于对照组(均P<0.001)；实验组患者不良反应发生率为1.72%(1/58)，与对照组3.44%(2/58)相比，差异不具有统计学意义(P>0.05)。结论：对于视网膜中央静脉阻塞患者，血栓通胶囊可有效改善患者的视网膜微循环、减轻黄斑水肿及降低ET-1水平，且安全性较高，不良反应的发生率低。
关键词： 血栓通胶囊；视网膜中央静脉阻塞；微循环；黄斑水肿；内皮素-1

Effect of Xueshuantong capsule on retinal microcirculation, macular edema, and endothelin-1 expression in patients with central retinal vein occlusion

Authors: 1XU Siqi, 1GONG Yuting, 1WANG Linnong, 1XU Yidan
1 Department of Ophthalmology, Nanjing Hospital Affiliated to Nanjing Medical University, Nanjing 210006, China

CorrespondingAuthor: WANG Linnong Email: linnongwang@aliyun.com

DOI: 10.3978/j.issn.2095-6959.2022.08.027

Abstract

Objective: To investigate the effect of Xueshuantong capsule on retinal microcirculation, macular edema, and endothelin-1 (ET-1) expression in patients with central retinal vein occlusion. Methods: A total of 116 patients with central retinal vein occlusion in Nanjing Hospital Affiliated to Nanjing Medical University from January 2018 to June 2021 were collected, and divided into an experimental group (n=58) and a control group (n=58) according to treatment methods. The control group received routine treatment, and the experimental group received Xueshuantong capsule on basis of routine treatment. Then, the retinal microcirculation parameters, macular retinal thickness, ET-1 levels, amplitude and latency of oscillatory potentials (OPs), and adverse reactions were compared. Results: After the treatment, there was an increase in peak systolic velocity (PSV) and end diastolic velocity (EDV) in both groups, and the increase was more significant in the experimental group than in the control group (P<0.001). The macular retinal thickness was decreased in both groups after the treatment, and the thickness was thinner in the experimental group compared with the control group (P<0.001). A decrease was found in ET-1 level in both groups after the treatment, and the experimental group had significantly lower ET-1 level than the control group (P<0.001). The amplitudes of the first 4 subwaves (OP1, OP2, OP3, and OP4) were increased in both groups after the treatment, and the increase was more remarkable in the experimental group than in the control group (all P<0.001). The latencies of OP1, OP2, and OP3 were reduced in both groups after the treatment, and the above values of the experimental group were obviously than lower those of the ontrol group (all P<0.001). The adverse reaction rate was 1.72% (1/58) in the experimental group, which showed no statistical difference with 3.44% (2/58) in the control group (P>0.05). Conclusion: For patients with central retinal vein occlusion, Xueshuantong capsule can effectively improve the retinal microcirculation, macular edema, and ET-1 level with high safety and low adverse reaction rate.

Keywords： Xueshuantong capsule; central retinal vein occlusion; microcirculation; macular edema; endothelin-1

文章选项

下载引文

分享